Finance

Lists
Why is RXRX up 2,48%?
Dive Deeper
RXRX:NASDAQ
Recursion Pharmaceuticals Inc
4,13 US$
+2,48%
(+0,100) 1D
4,15 US$
+0,47% (+0,020)
After hours
Closed: 30 სექ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RXRX...
Open
4,09 US$
High
4,29 US$
Low
3,98 US$
Mkt. cap
2,21 მლრდ.
Avg. vol.
19,15 მლნ.
Volume
32,64 მლნ.
52-wk high
7,18 US$
52-wk low
2,77 US$
EPS
-1,04 US$
Beta
1,08
Shares outstanding
535,34 მლნ.
No. of employees
600
Open
4,09 US$
High
4,29 US$
Low
3,98 US$
Mkt. cap
2,21 მლრდ.
Avg. vol.
19,15 მლნ.
Volume
32,64 მლნ.
52-wk high
7,18 US$
52-wk low
2,77 US$
EPS
-1,04 US$
Beta
1,08
Shares outstanding
535,34 მლნ.
No. of employees
600
News stories
From web sources and news partners
About Recursion Pharmaceuticals Inc
CEONajat Khan
Employees600
Founded2013
Headquartersსოლტ-ლეიკ-სიტი, იუტა, ამერიკის შეერთებული შტატები
Sector-
Analyst ratings
Based on 5 analysts giving stock ratings to RXRX in the past 3 months
Buy
Buy
2
Hold
3
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for RXRX in the last 3 months.
Highest
Current 4,13 US$
8,00 US$ (+93,70%)
Average
6,65 US$ (+61,02%)
Lowest
5,30 US$ (+28,33%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alec Stranahan
Bank of America Securities
Hold
Maintained
-
-
09/21/2026
Priyanka Grover
J.P. Morgan
Buy
Reiterated
-
-
09/15/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
5,30 US$
+28,3%
08/17/2026
Brendan Smith
TD Cowen
Hold
Maintained
-
-
08/05/2026
Gil Blum
Needham
Buy
Maintained
8,00 US$
+93,7%
08/05/2026
Last report
5 აგვ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-0,25 US$ / -0,23 US$
-6,84%miss
Revenue / Est. (USD)
7,67 მლნ. / 11,96 მლნ.
-35,89%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
5,18 მლნ.
35,54 მლნ.
6,47 მლნ.
7,67 მლნ.
Cost of goods sold
135,75 მლნ.
110,22 მლნ.
100,39 მლნ.
101,10 მლნ.
Cost of revenue
135,75 მლნ.
110,22 მლნ.
100,39 მლნ.
101,10 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
41,63 მლნ.
42,17 მლნ.
34,59 მლნ.
41,53 მლნ.
Operating expense
41,63 მლნ.
42,17 მლნ.
34,59 მლნ.
41,53 მლნ.
Total operating expenses
177,38 მლნ.
152,39 მლნ.
134,98 მლნ.
142,64 მლნ.
Operating income
-172,20 მლნ.
-116,85 მლნ.
-128,50 მლნ.
-134,97 მლნ.
Other non operating income
5,24 მლნ.
-6,03 მლნ.
784,00 ათ.
-1,04 მლნ.
EBT including unusual items
-162,25 მლნ.
-108,10 მლნ.
-122,11 მლნ.
-131,01 მლნ.
EBT excluding unusual items
-162,25 მლნ.
-116,62 მლნ.
-122,11 მლნ.
-131,01 მლნ.
Income tax expense
3,00 ათ.
20,00 ათ.
-4,60 მლნ.
-1,00 ათ.
Effective tax rate
-
-0,02%
3,77%
-
Other operating expenses
-
-
-
-
Net income
-162,25 მლნ.
-108,12 მლნ.
-117,50 მლნ.
-131,00 მლნ.
Net profit margin
-3 135,32%
-304,24%
-1 815,57%
-1 708,02%
Earnings per share
-0,36
-0,21
-0,22
-0,25
Interest and investment income
5,54 მლნ.
6,26 მლნ.
5,96 მლნ.
5,31 მლნ.
Interest expense
-833,00 ათ.
-
-350,00 ათ.
-309,00 ათ.
Net interest expenses
4,71 მლნ.
6,26 მლნ.
5,61 მლნ.
5,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-151,16 მლნ.
-97,37 მლნ.
-108,83 მლნ.
-116,80 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები